Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies – – Announc...
What short‑term price momentum or trading volume can be expected given the sentiment score of 65 and the news flow?
How does sevasemten's competitive landscape compare to other gene‑therapy candidates in development for muscular dystrophy?
Will the company update its guidance based on the recent top‑line data releases?
21 days ago